Femasys Inc
NASDAQ:FEMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Andersons Inc
NASDAQ:ANDE
|
US |
Femasys Inc
Cash from Financing Activities
Femasys Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Femasys Inc
NASDAQ:FEMY
|
Cash from Financing Activities
$25.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
96%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
-$395m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Financing Activities
-$956.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-20%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
$113m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$6.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
-$2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
What is Femasys Inc's Cash from Financing Activities?
Cash from Financing Activities
25.1m
USD
Based on the financial report for Dec 31, 2025, Femasys Inc's Cash from Financing Activities amounts to 25.1m USD.
What is Femasys Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
96%
Over the last year, the Cash from Financing Activities growth was 1 140%.
